Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

Completed · Not applicable

Conditions studied: Retinal Detachment, Vitreoretinopathy Proliferative

In brief

The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.

Key facts

Study ID

NCT01860586

Run by

Wills Eye

People needed

20

Starts

2013-06-01

Expected to finish

2014-11-01

Last updated by the study team

2017-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation.

You may not qualify if…

• Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery.
• Traction retinal detachment due to proliferative diabetic retinopathy.
• Inability to flatten retina completely intraoperatively
• Known allergy or contraindication to intravitreal bevacizumab

Where it is running

• Mid Atlantic Retina- Wills Eye Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.